| First Author | Zhang H | Year | 2020 |
| Journal | Cancer Discov | Volume | 10 |
| Issue | 2 | Pages | 288-305 |
| PubMed ID | 31771969 | Mgi Jnum | J:284071 |
| Mgi Id | MGI:6389218 | Doi | 10.1158/2159-8290.CD-19-0811 |
| Citation | Zhang H, et al. (2020) Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov 10(2):288-305 |
| abstractText | Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA. The function of these mutations has remained unresolved. We demonstrate that RHOA(Y42C), the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant, and that expression of RHOA(Y42C) with inactivation of the canonical tumor suppressor Cdh1 induces metastatic DGC in a mouse model. Biochemically, RHOA(Y42C) exhibits impaired GTP hydrolysis and enhances interaction with its effector ROCK. RHOA (Y42C) mutation and Cdh1 loss induce actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates YAP-TAZ, PI3K-AKT, and beta-catenin. RHOA(Y42C) murine models were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade. These results, coupled with sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a novel target for these cancers. SIGNIFICANCE: The functional significance of recurrent RHOA mutations in DGC has remained unresolved. Through biochemical studies and mouse modeling of the hotspot RHOA(Y42C) mutation, we establish that these mutations are activating, detail their effects upon cell signaling, and define how RHOA-mediated FAK activation imparts sensitivity to pharmacologic FAK inhibitors.See related commentary by Benton and Chernoff, p. 182.This article is highlighted in the In This Issue feature, p. 161. |
